Sirtris Pharmaceuticals to Present at the BIO CEO & Investor Conference February 12
08 February 2008 - 12:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that it will be presenting at the BIO CEO & Investor Conference
on Tuesday, February 12, 2008 at 11:00 am EST. The presentation
will be webcast live and can be accessed on the Sirtris website
(www.sirtrispharma.com) in the �Investor Relations� section. A
replay will be available approximately twenty-four hours after the
presentation and will be archived on the company's website for two
weeks. Sirtris recently announced positive Phase 1b clinical trial
results with drug candidate SRT501, a proprietary formulation of
resveratrol, in patients with Type 2 Diabetes. SRT501, which
targets the SIRT1 enzyme, was found to be safe and well-tolerated,
and significantly lowered glucose at the two-hour time point in an
oral glucose tolerance test conducted as part of the 28 day Phase
1b trial of patients with Type 2 Diabetes who were na�ve to
treatment. Sirtris� new chemical entities (NCEs) activate SIRT1 and
are chemically distinct from and 1000 times more potent, in vitro,
than resveratrol. The NCEs have been shown to lower glucose and
improve insulin sensitivity in predictive preclinical models of
Type 2 Diabetes. SIRT1 activators have the potential to be
frontline therapy for Type 2 Diabetes. Sirtris will discuss the
company's strategy for discovering and developing first-in-class
therapeutics that modulate sirtuins, a class of enzymes associated
with age-related diseases, as well as the company's clinical
progress. About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is
a biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
the Company believes control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators for diseases of aging, such as Type 2 Diabetes;
the progress and results of preclinical and clinical studies of
SIRT1 activators; development of first-in-class therapeutics that
modulate sirtuins, and the potential of sirtuin modulators to
receive regulatory approval. These forward-looking statements about
future expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company's product candidates will be
safe or effective, or receive regulatory approval, the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results, the Company's potential inability to
initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the Company to gain market acceptance of the Company's
product candidates, and those other risks factors that can be found
in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles